Potassium chloride
Identification
- Name
- Potassium chloride
- Accession Number
- DB00761
- Description
A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Potassium chloride (DB00761)
- Weight
- Average: 74.551
Monoisotopic: 73.932559568 - Chemical Formula
- ClK
- Synonyms
- Chlorid draselny
- Chloride of potash
- Kaliumchlorid
- KCl
- Monopotassium chloride
- Muriate of potash
- Sylvite
- External IDs
- B1653
- E 508
- E-508
- INS NO.508
- INS-508
- NSC-77368
Pharmacology
- Indication
For use as an electrolyte replenisher and in the treatment of hypokalemia.
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
- Mechanism of action
Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.
Target Actions Organism USolute carrier family 12 member 2 Not Available Humans USolute carrier family 12 member 1 binderHumans USolute carrier family 12 member 5 Not Available Humans USolute carrier family 12 member 6 Not Available Humans USolute carrier family 12 member 7 Not Available Humans USolute carrier family 12 member 4 Not Available Humans - Absorption
Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Potassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir Potassium chloride may decrease the excretion rate of Abacavir which could result in a higher serum level. Acarbose Acarbose may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Acebutolol Potassium chloride may increase the hyperkalemic activities of Acebutolol. Aceclofenac Aceclofenac may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Potassium chloride which could result in a higher serum level. Aclidinium The risk or severity of gastrointestinal ulceration can be increased when Aclidinium is combined with Potassium chloride. Acrivastine Potassium chloride may decrease the excretion rate of Acrivastine which could result in a higher serum level. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Take with a full glass of water.
- Take with food. This reduces gastrointestinal irritation.
Products
- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N Chloride ion ionic Q32ZN48698 16887-00-6 VEXZGXHMUGYJMC-UHFFFAOYSA-M - Product Images
- International/Other Brands
- Kaon Cl / Kaon-CL 10 / Micro-K / Sando-K / Slow-K
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataChlorure de potassium Proamp Injection, solution, concentrate 0.15 g/1mL Intravenous Laboratoire Aguettant 2018-07-31 Not applicable US 
Epiklor Powder, for solution 1.5 g/1.77g Oral Epic Pharma, LLC 2010-02-01 2013-10-01 US Epiklor/25 Powder, for solution 1.875 g/2.21g Oral Epic Pharma, LLC 2010-02-01 2013-09-01 US HUMCO Potassium Chloride 10 Percent Liquid 100 mg/1mL Oral Humco Holding Group. Inc. 1979-01-01 2015-12-31 US K + 45 Liquid Hemodialysis Baxter Laboratories 1990-12-31 Not applicable Canada 
K C1-rougier Liquid Oral Rougier Pharma Division Of Ratiopharm Inc 1967-12-31 1999-09-27 Canada K Lor Granules 20meq Powder, for solution Oral Abbott 1979-12-31 2008-06-06 Canada K-dur Tablet, extended release 1.5 g Oral Merck Ltd. 1989-12-31 2014-12-04 Canada K-dur Tablet, extended release 1500 mg/1 Oral Merck Sharp & Dohme Limited 1986-06-13 2008-10-31 US K-dur Tablet, extended release 750 mg/1 Oral Merck Sharp & Dohme Limited 1986-06-13 2008-10-31 US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataKlor Con M Tablet, extended release 750 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 1998-11-20 Not applicable US Klor Con M Tablet, extended release 1500 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 1998-11-20 Not applicable US 
Klor-Con Tablet, extended release 1500 mg/1 Oral Apace Packaging 2000-08-09 2014-09-30 US Klor-con Powder, for solution 1.5 g/1 Oral Upsher-Smith Laboratories, LLC 2017-10-23 Not applicable US Klor-con M Tablet, extended release 750 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 2014-09-01 Not applicable US Klor-con M Tablet, extended release 750 mg/1 Oral Cardinal Health 2014-09-01 2021-05-31 US Klor-Con M Tablet, extended release 1500 mg/1 Oral Physicians Total Care, Inc. 2005-08-15 2011-06-30 US Klor-con M Tablet, extended release 750 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2014-09-01 Not applicable US Klor-con M Tablet, extended release 1500 mg/1 Oral Upsher-Smith Laboratories, LLC 2011-01-18 Not applicable US Klor-con M Tablet, extended release 750 mg/1 Oral REMEDYREPACK INC. 2020-01-29 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataHi Potency Potassium Chloride Tablet, extended release Oral Swiss Herbal Remedies Ltd. 1997-02-24 2001-08-02 Canada Kaochlor-20 Solution Oral Pfizer Canada Ulc 1995-12-31 2006-08-02 Canada Micro-K-10 Extencaps Src 750mg Capsule, extended release Oral Wyeth Ayerst Canada Inc. 1994-12-31 2003-07-28 Canada Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image (20 Mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USP Potassium chloride (150 mg) + Dextrose, unspecified form (3.3 g) + Sodium chloride (300 mg) Solution Intravenous Baxter Laboratories 1978-12-31 Not applicable Canada (20 Mmol/l) Potassium Chloride In 5% Dextrose and 0.9% Sodium Chloride Injection USP Potassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (900 mg) Solution Intravenous Baxter Laboratories 1990-12-31 Not applicable Canada (20 Mmol/l) Potassium Chloride In 5% Dextrose Injection USP Potassium chloride (150 mg) + Dextrose, unspecified form (5 g) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (20mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USP Potassium chloride (150 mg) + Sodium chloride (900 mg) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (20mmol/l) Potassium Chloride In 5% Dextrose and 0.2% Sodium Chloride Injection USP Potassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (200 mg) Solution Intravenous Baxter Laboratories 1989-12-31 2016-07-15 Canada (20mmol/l) Potassium Chloride In 5% Dextrose and 0.45% Sodium Chloride Injection USP Potassium chloride (150 mg) + Dextrose, unspecified form (5 g) + Sodium chloride (450 mg) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (40 Mmol/l) Potassium Chloride In 0.9% Sodium Chloride Injection USP Potassium chloride (300 mg) + Sodium chloride (900 mg) Liquid Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (40 Mmol/l) Potassium Chloride In 5% Dextrose Injection USP Potassium chloride (300 mg) + Dextrose, unspecified form (5 g) Solution Intravenous Baxter Laboratories 1989-12-31 Not applicable Canada (40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USP Potassium chloride (328 mg) + Calcium chloride (20 mg) + Sodium lactate (310 mg) + Sodium chloride (600 mg) Solution Intravenous Baxter Laboratories 2002-12-11 2016-07-15 Canada (40mmol/l) Potassium Chloride In 3.3% Dextrose and 0.3% Sodium Chloride Injection USP Potassium chloride (300 mg) + Dextrose, unspecified form (3.3 g) + Sodium chloride (300 mg) Solution Intravenous Baxter Laboratories 1978-12-31 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Chlorure de potassium Proamp Potassium chloride (0.15 g/1mL) Injection, solution, concentrate Intravenous Laboratoire Aguettant 2018-07-31 Not applicable US Cytosol Ophthalmics - Balanced Salt Solution Potassium chloride (75 mg/1mL) + Calcium chloride dihydrate (48 mg/1mL) + Magnesium chloride hexahydrate (30 mg/1mL) + Sodium acetate trihydrate (3.90 mg/1mL) + Sodium chloride (6.40 mg/1mL) + Sodium citrate dihydrate (1.70 mg/1mL) Solution Irrigation Biomet Biologics 2010-01-01 2010-09-04 US Effervescent Potassium Chloride Potassium chloride (1.25 g/1) + L-Lysine hydrochloride (1.5 g/1) + Potassium bicarbonate (0.7 g/1) Tablet, effervescent Oral Qualitest 2006-01-06 2021-07-31 US Epiklor Potassium chloride (1.5 g/1.77g) Powder, for solution Oral Epic Pharma, LLC 2010-02-01 2013-10-01 US Epiklor/25 Potassium chloride (1.875 g/2.21g) Powder, for solution Oral Epic Pharma, LLC 2010-02-01 2013-09-01 US Glysol-500 Potassium chloride (0.03 g/100mL) + Glycerin (57.10 g/100mL) + Sodium lactate (1.60 g/100mL) Solution Extracorporeal Biomet Biologics 2010-01-01 2010-09-06 US HUMCO Potassium Chloride 10 Percent Potassium chloride (100 mg/1mL) Liquid Oral Humco Holding Group. Inc. 1979-01-01 2015-12-31 US HydroGold 9 Potassium chloride (0.01 mg/100mg) + Acetyl hexapeptide-3 (0.01 mg/100mg) + Adenosine (0.04 mg/100mg) + Allantoin (0.2 mg/100mg) + Sodium benzoate (0.5 mg/100mg) + Butylene glycol (2 mg/100mg) + Castor oil (0.4 mg/100mg) + Dimethicone (0.01 mg/100mg) + Glycerin (20 mg/100mg) + Gold (0.0001 mg/100mg) + Nicotinamide (2 mg/100mg) + Phenoxyethanol (0.5 mg/100mg) + Titanium dioxide (0.43 mg/100mg) + Xanthan gum (0.5 mg/100mg) Patch Topical Bhmbg Global Branding Inc. 2018-03-09 2019-12-31 US K-Sol Potassium chloride (40 meq/15mL) Liquid Oral Laser Pharmaceuticals Llc 2015-01-22 2015-12-31 US K-Sol Potassium chloride (20 meq/15mL) Liquid Oral Laser Pharmaceuticals Llc 2015-01-22 2015-12-31 US
Categories
- ATC Codes
- A12BA51 — Potassium chloride, combinationsB05XA01 — Potassium chloride
- B05XA — Electrolyte solutions
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Acids
- Acids, Noncarboxylic
- Agents causing hyperkalemia
- Alimentary Tract and Metabolism
- Anions
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Chlorides
- Chlorine Compounds
- Drugs that are Mainly Renally Excreted
- Electrolyte Solutions
- Electrolytes
- Hemodialysis Solution
- I.V. Solution Additives
- Ions
- Mineral Supplements
- Minerals
- Potassium Compounds
- Potassium Salt
- Replacement Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal salts
- Sub Class
- Alkali metal chlorides
- Direct Parent
- Alkali metal chlorides
- Alternative Parents
- Inorganic chloride salts
- Substituents
- Alkali metal chloride / Inorganic chloride salt / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- potassium salt, inorganic chloride (CHEBI:32588)
Chemical Identifiers
- UNII
- 660YQ98I10
- CAS number
- 7447-40-7
- InChI Key
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M
- InChI
- InChI=1S/ClH.K/h1H;/q;+1/p-1
- IUPAC Name
- potassium chloride
- SMILES
- [Cl-].[K+]
References
- Synthesis Reference
Fritz Hagedorn, Gerd Peuschel, Arno Singewald, "Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent." U.S. Patent US5057208, issued July, 1955.
US5057208- General References
- Not Available
- External Links
- KEGG Drug
- D02060
- PubChem Compound
- 4873
- PubChem Substance
- 46506038
- ChemSpider
- 4707
- 8591
- ChEBI
- 32588
- ChEMBL
- CHEMBL1200731
- Therapeutic Targets Database
- DAP000828
- PharmGKB
- PA451055
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Potassium_chloride
- AHFS Codes
- 40:34.00* — Hemodialysis Solution
- 88:29.00* — Minerals
- 40:12.00 — Replacement Preparations
- FDA label
- Download (632 KB)
- MSDS
- Download (72.6 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Colonoscopy 1 4 Completed Basic Science Blood Pressures / High Blood Pressure (Hypertension) 1 4 Completed Basic Science Functional Constipation / Irritable Bowel Syndrome Characterized by Constipation 1 4 Completed Diagnostic Colon Adenomas / Colon Lesion / Colon Polyps 1 4 Completed Screening Colorectal Cancers 1 4 Completed Treatment Atrial Fibrillation (AF) / Flutter, Atrial 1 4 Completed Treatment Bowel Preparation for Colonoscopy 1 4 Completed Treatment Cesarean Section / Hypotension / Pregnancy / Spinal Anaesthesia 1 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Colon Cleansing for Colonoscopy 1
Pharmacoeconomics
- Manufacturers
- Novo nordisk inc
- Savage laboratories inc div altana inc
- Kv pharmaceutical co
- Teva pharmaceuticals usa inc
- Watson laboratories inc florida
- Abraxis pharmaceutical products
- Akorn inc
- App pharmaceuticals llc
- B braun medical inc
- Baxter healthcare corp anesthesia and critical care
- Baxter healthcare corp
- Gd searle llc
- Hospira inc
- International medication system
- Eli lilly and co
- Luitpold pharmaceuticals inc
- Miles laboratories inc
- Pharma serve inc sub torigian laboratories
- Watson laboratories inc
- Future pak ltd
- Upsher smith laboratories inc
- Apothecon inc div bristol myers squibb
- Abbott laboratories pharmaceutical products div
- Copley pharmaceutical inc
- Eurand america inc
- Schering corp
- Novartis pharmaceuticals corp
- Upsher-Smith Laboratories Inc.
- Packagers
- Abbott Laboratories Ltd.
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Alaven Pharmaceutical
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apace Packaging
- Apothecon
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- B. Braun Melsungen AG
- Baxter International Inc.
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Cardinal Health
- Caremark LLC
- Century Pharmaceuticals Inc.
- Chemrich Laboratories Inc.
- Comprehensive Consultant Services Inc.
- Corvit Pharmaceuticals
- Coupler Enterprises Inc.
- Dept Health Central Pharmacy
- DHHS Program Support Center Supply Service Center
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Edwards Pharmaceuticals
- Epic Pharma LLC
- Ethex Corp.
- Eurand Pharmaceuticals Inc.
- Forest Pharmaceuticals
- General Injectables and Vaccines Inc.
- H and H Laboratories
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hospira Inc.
- Humco
- John Ross Chemical Ltd.
- Kaiser Foundation Hospital
- KV Pharmaceutical Co.
- Laboratoires Upsa
- Lake Erie Medical and Surgical Supply
- Legacy Pharmaceuticals Packaging LLC
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mallinckrodt Inc.
- Mckesson Corp.
- Mead Johnson and Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Neighborcare Repackaging Inc.
- Neuman Distributors Inc.
- Novartis AG
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Association
- Pharmaceutical Packaging Center
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmacia Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Qualitest
- Rebel Distributors Corp.
- Remedy Repack
- Sandhills Packaging Inc.
- Sandoz
- Savage Labs
- Schering Corp.
- Schering-Plough Inc.
- Southwood Pharmaceuticals
- Summit Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Ther-Rx Corp.
- Tower Laboratories Ltd.
- Tya Pharmaceuticals
- United Research Laboratories Inc.
- Upsher Smith Laboratories
- Va Cmop Dallas
- Vangard Labs Inc.
- Vintage Pharmaceuticals Inc.
- Warrick Pharmaceuticals Corp.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Dosage Forms
Form Route Strength Solution Intravenous 5 % Injection, solution Intravenous 150 mg/100mL Liquid Intravenous Injection, solution Intravenous 300 mg/100mL Solution Hemodialysis Liquid Hemodialysis Tablet, extended release Oral 750 mg Solution Intravenous 0.25 g/mL Injection, solution Intravenous 2.5 g/500mL Powder, for solution Intraocular Solution Intraocular Solution Oral 289.2 mg Solution Oral 5 mg/1mL Solution Solution Ophthalmic Solution Intraocular; Irrigation 1950 mg Kit; powder, for solution; tablet, delayed release Oral Solution 5 % Solution Intravenous 0.64 g/100ml Solution Intravenous 5 g/100ml Solution Intravenous 0.86 g/100ml Solution Intravenous 50 g/L Solution Intravenous 3.1 g/L Injection, solution Intravenous 3.1 g/L Solution Irrigation 48 mg/100mL Kit; solution Intraocular Solution Intra-arterial Solution 6340 mg/L Injection, solution, concentrate Intravenous 0.15 g/1mL Solution Intravenous 1.491 g Solution Intravenous 20 mEq/mL Solution 970 mg/100mL Powder, for solution Nasogastric Powder, for solution Oral 45 g/750mL Solution Irrigation Injection, solution 3.25 g/1mL Solution Intravenous 6.4 g/L Injection Intravenous Solution Intravenous 4.21 g/1000ml Tablet, effervescent Oral Solution Oral 12.27 g/100mL Powder Oral Solution Intrathecal Injection Intrathecal Powder Oral 52.5 g Powder, for solution Oral 2.9 g Tablet, delayed release Oral 500 mg Solution Oral 0.294 g Powder, for solution Oral 1.5 g/1.77g Powder, for solution Oral 1.875 g/2.21g Solution Intravenous 1.63 g Powder Oral 13.5 g Spray Oral 7.3 mg/50mL Solution Unknown Solution Extracorporeal Powder, for solution Nasogastric; Oral Solution, concentrate 9 g/1L Solution, concentrate 6.43 g/1L Solution Oral 30 mg Solution Oral 0.29 g Solution Oral 0.275 g Solution Oral 275 mg Liquid Oral 100 mg/1mL Patch Topical Solution Intravenous 3 g Solution Intravenous 0.31 % Solution Intravenous 0.02 g Liquid Intraocular Solution 0.64 g/100ml Solution Intravenous 0.64 % Solution Intravenous 0.03 % Solution Intravenous 0.37 % Solution Intravenous Liquid Hemodialysis Tablet, extended release Oral 1.5 g Powder, for solution Oral Tablet Oral Liquid Oral 20 meq/15mL Liquid Oral 40 meq/15mL Tablet, film coated, extended release Oral 1500 mg/1 Tablet, film coated, extended release Oral 750 mg/1 Injection, solution, concentrate Intravenous 1.5 g/10mL Injection, solution, concentrate Intravenous 150 mg/1mL Solution Intravenous 0.07 g Injection, emulsion Intravenous Injection Intravenous 110 g Injection Intravenous 165 g Injection Intravenous 220 g Injection Intravenous 275 g Injection Intravenous 107 g Injection Intravenous 143 g Injection Intravenous 178 g Capsule, extended release Oral 600 mg Tablet, extended release Oral Injection, solution, concentrate Intravenous 74.5 mg/ml Injection, solution, concentrate Intravenous 15 % Solution Intravenous 8.6 % Solution Oral Capsule 840 mg Injection, solution, concentrate Intravenous 200 meq/100mL Solution Oral 1 meq/1mL Syrup 10 g/100mL Solution Oral 5 mg/100mL Solution Oral 60 mg/5mL Tablet, extended release Oral 600 MG Tablet, sugar coated Oral 600 mg Powder, for solution Oral 1.685 g Powder, for solution Oral 1.875 g/1 Powder, for solution Oral 20 meq/1 Tablet, extended release Oral 750 mg/1 Tablet, extended release Oral 10 meq/1 Tablet, extended release Oral 1125 mg/1 Tablet, extended release Oral 20 meq/1 Solution Intravenous 20.475 % Tablet, film coated, extended release Oral Injection, solution Intravenous 30 mg/100mL Solution, for slush Irrigation Solution Intravenous 20 mg Solution Intravenous; Irrigation 0.2 mg Injection, solution Intravenous 50 mg/mL Injection, solution Intravenous 3 g/L Injection, solution Intravenous 3.14 g/L Solution Intravenous 7.5 % Powder Oral 3.5 g Solution Oral 20 meq/30mL Powder Oral 5 g/100mL Powder, for solution Oral 13.125 G Emulsion Topical Capsule, extended release Oral Capsule, extended release Oral 750 mg/1 Capsule, extended release Oral 600 mg/1 Liquid Buccal Spray Buccal Solution Oral 13.125 g Powder, for solution Oral 6.563 G Kit Oral Solution Oral 100 g Solution Intravenous 0.368 g Kit; solution Intraocular; Irrigation Granule, effervescent Oral Solution Intravenous 55 g/L Solution Intravenous 5.5 g/100ml Solution 0.53 g/100ml Solution Intravenous 0.86 % Solution 16 g/L Powder, for solution Oral 118 g Injection, emulsion Intravenous 1.6 g/100mL Injection, emulsion; injection, solution Intravenous 3.2 g/100mL Injection, solution, concentrate Intravenous Solution Oral Injection, emulsion Intravenous 1.6 g Injection Intravenous 2.27 g/l Injection Intravenous 4.12 g/l Solution Intravenous 7.14 g Solution Intravenous 9.52 g Solution Intravenous 11.9 g Emulsion Intravenous 6.41 g Emulsion Intravenous 9.61 g Emulsion Intravenous 12.82 g Emulsion Intravenous 4 g Solution Intraocular; Ophthalmic 7.8 mg Powder, for solution Oral 59 g Syrup 0.447 meq/1mL Solution Oral 294 mg Solution Oral 29.4 mg Powder, for solution Oral 120 g/129.2g Liquid Oral Emulsion Intravenous Emulsion Intravenous 3 g Injection, solution Intravenous 5 % Irrigant Irrigation Solution Intravenous 368 mg Injection, solution Intravenous Injection, solution Intra-arterial Solution Solution Intravenous 0.035 % Injection, solution Intravenous 0.03 % Solution 3.2 g/100mL Solution 1.6 g/100mL Powder, for solution Oral Solution Oral 500 mg/5mL Injection, solution Intravenous 22.5 % Injection, solution Intravenous 7.5 % Syrup 500 mg/5mL Capsule Oral 750 mg/1 Capsule, coated, extended release Oral 10 meq/1 Capsule, coated, extended release Oral 8 meq/1 Capsule, extended release Oral 10 meq/1 Capsule, extended release Oral 8 meq/1 For solution Oral 1.5 g/1.58g For solution Oral 1.5 g/1.54g Injection Intravenous 150 g/1000mL Injection, solution 1.5 g/10mL Injection, solution 15 g/100mL Injection, solution 40 meq/20mL Injection, solution Intravenous 10 meq/100mL Injection, solution Intravenous 14.9 g/1000mL Injection, solution Intravenous 200 meq/1000mL Injection, solution Intravenous 22.4 g/1000mL Injection, solution Intravenous 29.8 g/1000mL Injection, solution Intravenous 30 meq/100mL Injection, solution Intravenous 400 meq/1000mL Injection, solution Intravenous 7.46 g/1000mL Injection, solution, concentrate Intravenous 149 mg/1mL Injection, solution, concentrate Intravenous 2 meq/1mL Injection, solution, concentrate Parenteral 14.9 g/100mL Liquid Oral 40 meq/30mL Powder Oral 20 meq/1.5g Powder, for solution Oral 1.5 g/1.74g Powder, for solution Oral 1.5 g/1 Powder, for solution Oral 25 meq/1 Solution Oral 1.3 meq/1mL Solution Oral 1.5 g/15mL Solution Oral 10 g/100mL Solution Oral 2.6 meq/1mL Solution Oral 20 meq/15mL Solution Oral 3 g/15mL Solution Oral 40 meq/15mL Syrup 1 meq/1mL Tablet 500 mg Tablet Oral 10 meq/1 Tablet Oral 1125 mg/1 Tablet Oral 1500 mg/1 Tablet Oral 750 mg/1 Tablet, extended release Oral 1500 mg/1 Tablet, extended release Oral 8 meq/1 Tablet, film coated, extended release Oral 10 meq/1 Tablet, film coated, extended release Oral 600 mg/1 Tablet, film coated, extended release Oral 8 meq/1 Solution Oral 10 mg/100mL Solution Oral 3 mg/100mL Solution Oral 375 mg/5mL Solution Oral 7.5 g/100mL Solution Oral 13 meq/15mL Tablet Oral 20 meq/1 Capsule Oral 600 mg/1 Powder, for solution Oral 1.5 g/1.58g Solution Intravenous Liquid Intravenous Injection Solution Oral 6.67 g/100mL Powder Hemodialysis Injection, solution, concentrate Intravenous 20 meq/10mL Injection, solution, concentrate Intravenous 40 meq/20mL Injection 225 mg/1ml Injection 75 mg/1ml Solution Oral 40 meq/30mL Tablet Kit Hemodialysis Solution Hemodialysis; Intravenous Injection, solution Intravenous 0.86 g/100mL Solution Parenteral 3 g/100ml Douche Vaginal Solution Intravenous 0.6 g/100ml Solution Intravenous 0.31 g/100ml Solution Irrigation; Topical 20 mg Injection, solution Intravenous 20 mg/100mL Injection, solution 20 mg/100mL Liquid Oral Solution Buccal; Oral; Topical 16.2 mg Aerosol Oral Granule 700 mg Granule 50 gr Tablet, extended release Oral 600 mg/1 Emulsion Parenteral 50 g Solution Intravenous 0.2 mg Solution Intravenous 6 mg Solution Intravenous 33 mg Solution Conjunctival; Ophthalmic 12.5 mg Solution Intraocular; Irrigation 0.39 g Injection, solution Intracardiac 13.54 mg/20mL Tablet Oral Liquid Irrigation Powder, for solution Oral 1.43 g Solution Intravenous; Irrigation 0.62 g/100ml Solution Intravenous 10 mg/2ml Solution Intravenous 6 g/100mL Injection, solution Intravenous 30 g/500mL - Prices
Unit description Cost Unit Klor-Con 100 20meq Packets Box 106.77USD box Kay Ciel 30 20meq Packets Box 58.99USD box Rum-K-SF 15% Liquid 473ml Bottle 45.98USD bottle Klor-Con 30 25meq Packets Box 36.99USD box Colyte 240 gm Solution 26.0USD bottle Colyte-Flavored 240 gm Solution 18.17USD bottle K-Lor 20meq Packets 1.92USD packet K-lyte tablet eff 1.43USD tablet K-lyte-cl 25 meq tablet eff 1.43USD tablet Micro-K 10meq capsule 1.41USD capsule Micro-K 8meq capsule 1.21USD capsule Potassium cl 25 meq tablet eff 0.94USD tablet Micro-k 10 meq extencaps 0.91USD each Potassium Chloride CR 10meq capsule 0.9USD capsule Potassium Chloride CR 8meq capsule 0.87USD capsule K-Tabs 10meq Controlled Release Tabs 0.68USD tab K-tab er 10 meq tablet 0.66USD tablet Kaochlor-eff 20 meq tablet 0.59USD tablet K-tab 10 meq tablet sa 0.58USD tablet K-Lyte 25 meq Effervescent Tablet 0.58USD tablet Klor-con m20 tablet 0.57USD tablet Klor-Con/EF 25meq Effervescent Tabs 0.57USD tab Klor-Con 8meq Controlled Release Tabs 0.56USD tab Klor-Con M20 20meq Controlled Release Tabs 0.55USD tab Potassium Chloride Crys CR 20meq Controlled Release Tabs 0.53USD tab Potassium cl 20 meq tablet er 0.52USD tablet Potassium cl 20 meq tablet sa 0.52USD tablet Klor-con 10 meq tablet 0.5USD tablet Klor-con m15 tablet 0.5USD tablet Klotrix 10meq Controlled Release Tabs 0.5USD tab Potassium cl er 20 meq tablet 0.49USD tablet Klor-con-ef 25 meq tablet eff 0.4USD tablet Micro-k 8 meq extencaps 0.34USD each Kaon-Cl-10 10meq Controlled Release Tabs 0.3USD tab Klor-con m10 tablet 0.3USD tablet Potassium cl er 10 meq tablet 0.3USD tablet Potassium cl 10 meq tablet sa 0.29USD tablet Potassium Chloride Crys CR 10meq Controlled Release Tabs 0.28USD tab Potassium Chloride CR 10meq Controlled Release Tabs 0.27USD tab Potassium cl er 8 meq tablet 0.26USD tablet Kaon-cl 10 meq tablet sa 0.23USD tablet Potassium cl 2 meq/ml vial 0.23USD ml K-Dur 20 meq Sustained-Release Tablet 0.21USD tablet Potassium Chloride CR 8meq Controlled Release Tabs 0.18USD tab Klor-con 8 meq tablet 0.16USD tablet Slow K 8 meq Sustained-Release Tablet 0.16USD tablet Micro-K Extencaps 8 meq Sustained-Release Capsule 0.1USD capsule Apo-K 8 meq Sustained-Release Tablet 0.09USD tablet Potassium Chloride 40 Meq/15ml(20%) Liquid 0.06USD ml Potassium Chloride 20 Meq/15ml(10%) Liquid 0.03USD ml Potassium chloride crystals 0.02USD g K-10 Oral Liquid 1.33 meq/ml Liquid 0.02USD ml Colyte with flavor packets 0.01USD ml Pms - Potassium Chloride 1.33 meq/ml Liquid 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region Unlock Additional DataUS7291324 No 2007-11-06 2022-10-22 US US7169381 No 2007-01-30 2024-09-01 US US7658914 No 2010-02-09 2024-09-01 US US7084130 No 2006-08-01 2021-11-29 US US9326969 No 2016-05-03 2033-09-10 US US9592252 No 2017-03-14 2032-08-11 US US9707297 No 2017-07-18 2033-09-10 US US8999313 No 2015-04-07 2033-09-10 US US10016504 No 2018-07-10 2033-09-10 US US10646512 No 2012-03-25 2032-03-25 US Additional Data Available- Filed On
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 770 °C Not Available water solubility Freely soluble Not Available - Predicted Properties
Property Value Source logP 0.2 ChemAxon pKa (Strongest Acidic) -7 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 0 m3·mol-1 ChemAxon Polarizability 1.78 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9445 Blood Brain Barrier + 0.975 Caco-2 permeable + 0.6764 P-glycoprotein substrate Non-substrate 0.9039 P-glycoprotein inhibitor I Non-inhibitor 0.9891 P-glycoprotein inhibitor II Non-inhibitor 0.9866 Renal organic cation transporter Non-inhibitor 0.9219 CYP450 2C9 substrate Non-substrate 0.8116 CYP450 2D6 substrate Non-substrate 0.717 CYP450 3A4 substrate Non-substrate 0.7571 CYP450 1A2 substrate Non-inhibitor 0.7551 CYP450 2C9 inhibitor Non-inhibitor 0.8594 CYP450 2D6 inhibitor Non-inhibitor 0.9314 CYP450 2C19 inhibitor Non-inhibitor 0.8365 CYP450 3A4 inhibitor Non-inhibitor 0.9576 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9002 Ames test Non AMES toxic 0.6808 Carcinogenicity Carcinogens 0.7523 Biodegradation Ready biodegradable 0.6815 Rat acute toxicity 1.9786 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9433 hERG inhibition (predictor II) Non-inhibitor 0.9634
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A2
- Uniprot ID
- P55011
- Uniprot Name
- Solute carrier family 12 member 2
- Molecular Weight
- 131445.825 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A1
- Uniprot ID
- Q13621
- Uniprot Name
- Solute carrier family 12 member 1
- Molecular Weight
- 121449.13 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
- Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
- Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
- Gene Name
- SLC12A5
- Uniprot ID
- Q9H2X9
- Uniprot Name
- Solute carrier family 12 member 5
- Molecular Weight
- 126182.49 Da
References
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
- Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Rubidium ion transmembrane transporter activity
- Specific Function
- Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
- Gene Name
- SLC12A6
- Uniprot ID
- Q9UHW9
- Uniprot Name
- Solute carrier family 12 member 6
- Molecular Weight
- 127615.745 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
- Gene Name
- SLC12A7
- Uniprot ID
- Q9Y666
- Uniprot Name
- Solute carrier family 12 member 7
- Molecular Weight
- 119104.84 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
- Gene Name
- SLC12A4
- Uniprot ID
- Q9UP95
- Uniprot Name
- Solute carrier family 12 member 4
- Molecular Weight
- 120648.73 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A2
- Uniprot ID
- P55011
- Uniprot Name
- Solute carrier family 12 member 2
- Molecular Weight
- 131445.825 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. [PubMed:12920401]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A1
- Uniprot ID
- Q13621
- Uniprot Name
- Solute carrier family 12 member 1
- Molecular Weight
- 121449.13 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. [PubMed:16093448]
- Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. [PubMed:16713495]
- Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. [PubMed:16807401]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport in mature neurons. Transport occurs under isotonic conditions, but is activated 20-fold by cell swelling. Important for Cl(-) homeostasis in n...
- Gene Name
- SLC12A5
- Uniprot ID
- Q9H2X9
- Uniprot Name
- Solute carrier family 12 member 5
- Molecular Weight
- 126182.49 Da
References
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. [PubMed:17134779]
- Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. [PubMed:16936706]
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. [PubMed:17008020]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Rubidium ion transmembrane transporter activity
- Specific Function
- Mediates electroneutral potassium-chloride cotransport. May be activated by cell swelling. May contribute to cell volume homeostasis in single cells.
- Gene Name
- SLC12A6
- Uniprot ID
- Q9UHW9
- Uniprot Name
- Solute carrier family 12 member 6
- Molecular Weight
- 127615.745 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May mediate K(+) uptake into Deiters' cells in the cochlea and contribute to K(+) recycling in the inner ear....
- Gene Name
- SLC12A7
- Uniprot ID
- Q9Y666
- Uniprot Name
- Solute carrier family 12 member 7
- Molecular Weight
- 119104.84 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Protein kinase binding
- Specific Function
- Mediates electroneutral potassium-chloride cotransport when activated by cell swelling. May contribute to cell volume homeostasis in single cells. May be involved in the regulation of basolateral C...
- Gene Name
- SLC12A4
- Uniprot ID
- Q9UP95
- Uniprot Name
- Solute carrier family 12 member 4
- Molecular Weight
- 120648.73 Da
References
- Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. [PubMed:16949074]
- Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. [PubMed:17418819]
- Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. [PubMed:16943364]
Drug created on June 13, 2005 07:24 / Updated on October 19, 2020 07:47
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates